Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer

BACKGROUND: To assess the efficacy and safety of individualised dose optimisation of irinotecan monotherapy as salvage treatment for advanced gastric cancer (AGC). METHODS: A total of 43 patients were enrolled. Intravenous irinotecan (350 mg m(−2)) was administered every 3 weeks. The dose was increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, J-C, Lee, J-L, Ryu, M-H, Chang, H M, Kim, M, Lee, H J, Kim, H-S, Shin, J-G, Kim, T-W, Kang, Y-K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349177/
https://www.ncbi.nlm.nih.gov/pubmed/22516947
http://dx.doi.org/10.1038/bjc.2012.143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349177/
https://www.ncbi.nlm.nih.gov/pubmed/22516947
http://dx.doi.org/10.1038/bjc.2012.143

Ejemplares similares